Treatment of internal disc disruption and connective tissue injuries
OwnerBjorn Eekinventor
Life of this patent
Estimating the term…
Abstract
This disclosure relates to treating internal disc disruption or a connective tissue injury. The treatment involves injecting, or otherwise administering, a therapeutic composition into an animal, such as a human being, in need thereof. The therapeutic composition may contain transforming growth factor beta 1 (TGF-β1) or transforming growth factor beta 2 (TGF-β2), fibroblast growth factor (FGF), and a pharmaceutically acceptable excipient or a secondary agent.
Claims17
A therapeutic composition comprising Transforming growth factor beta 1 (TGF-β1) or Transforming growth factor beta 1 (TGF-β2), Fibroblast growth factor (FGF), water, and at least 2 of the following excipients or secondary agents:
- dextrose, lidocaine, chondroitin, carboxymethyl cellulose, glucosamine, hyaluronic acid, and a buffer.
Dependencies are inferred from the claim text.